WATERTOWN, Mass., June 23, 2022 (GLOBE NEWSWIRE) — EyePoint Prescribed drugs, Inc. (NASDAQ: EYPT), a pharmaceutical firm engaged within the improvement and commercialization of therapies to enhance the lives of sufferers with critical eye issues, has at this time introduced the election of Anthony (Tony) Adamis, MD to its Board of Administrators. Dr. Adamis is a extremely completed ophthalmology govt with over 30 years of analysis and improvement expertise within the biopharmaceutical trade.
“Dr. Adamis is a pioneer within the discovery and early improvement of anti-VEGF medication for the remedy of ophthalmic illnesses and will likely be a useful member of our Board of Administrators,” stated Nancy Lurker, CEO of EyePoint Prescribed drugs. “Tony brings an distinctive monitor document guiding the event of 20 medication and 25 U.S. Meals and Drug Administration approvals, and we stay up for leveraging his experience as we proceed to develop our enterprise and make advancing our lead pipeline asset, EYP-1901, via the clinic for a number of ophthalmic indications.
“I’m happy to welcome Dr. Adamis to the EyePoint Board of Administrators,” stated Dr. Göran Ando, MD, Chairman of the Board of EyePoint Prescribed drugs. “Tony’s scientific and operational expertise in growing revolutionary eye therapies, from preliminary discovery to industrial phases, uniquely positions him to make a beneficial contribution as we work in the direction of EyePoint’s objective of changing into the chief ocular drug supply expertise On behalf of the Board of Administrators, we’re delighted to have Tony’s experience and stay up for working with him.
Dr. Adamis is greatest identified for his co-discovery of the position of vascular endothelial progress issue (VEGF) in eye illnesses, together with age-related macular degeneration (AMD) and diabetic retinopathy. Previous to becoming a member of EyePoint’s Board of Administrators, Dr. Adamis held numerous positions at Genentech/Roche, most just lately as Senior Vice President, Developmental Innovation, and led the primary FDA-approved medication for the diabetic macular edema and diabetic retinopathy, amongst others. . Beforehand, he was co-founder, director, president and CEO of Jerini Ophthalmic. Dr. Adamis additionally co-founded EyeTech Prescribed drugs, which gained FDA approval for the primary anti-VEGF drug in ophthalmology, and was acquired by OSI Prescribed drugs in 2005. At present, Dr. Adamis is a lecturer within the Division of Harvard Medical Faculty Ophthalmology. . Dr. Adamis holds an MD with honors from the College of Chicago, Pritzker Faculty of Drugs, and accomplished his ophthalmology residency on the College of Michigan and postgraduate coaching at Harvard Medical Faculty. He holds a BS in Biology from the College of Illinois, Urbana-Champaign.
“I’m delighted to affix EyePoint at this essential time, as the corporate is about to develop its medical trials for EYP-1901, an investigational, long-acting intravitreal anti-VEGF remedy, for the potential remedy of a number of ophthalmic indications. , together with moist AMD,” stated Dr. Tony Adamis, MD “I stay up for supporting the corporate’s mission to enhance the lives of sufferers with critical eye issues and to convey revolutionary merchandise to sufferers in the USA. And on the planet.”
Dr. Adamis was elected to the board by the corporate’s shareholders on the firm’s annual assembly held earlier at this time, together with a slate of returning administrators.
EYP-1901 is being developed as an investigational sustained-release remedy, initially in moist age-related macular degeneration, combining a bioerodible formulation of EyePoint’s proprietary Durasert® supply expertise with vorolanib, a tyrosine kinase inhibitor. Constructive eight-month interim security and efficacy information from the continuing DAVIO Part 1 medical trial of EYP-1901 confirmed no stories of ocular or drug-related systemic SAEs and no toxicity dose limiting with secure visible acuity and OCT. Moreover, 53% and 41% of eyes didn’t require further anti-VEGF injections for as much as six and 9 months, respectively, after a single dose of EYP-1901. Part 2 medical trials are scheduled for moist AMD in Q3 2022 and in diabetic retinopathy in 2H 2022. Vorolanib is licensed to EyePoint solely by Equinox Sciences for the localized remedy of all ophthalmic illnesses.
About EyePoint Prescribed drugs
EyePoint Prescribed drugs (Nasdaq: EYPT) is a pharmaceutical firm engaged within the improvement and commercialization of therapeutic merchandise to assist enhance the lives of sufferers with critical eye issues. The Firm’s pipeline depends on its wholly owned Durasert® expertise for extended intraocular drug supply, together with EYP-1901, an investigational extended intravitreal anti-VEGF remedy initially concentrating on moist age-related macular degeneration. The confirmed Durasert drug supply platform has been safely delivered to hundreds of affected person eyes via 4 US FDA-approved merchandise, together with YUTIQ® for the remedy of power non-infectious uveitis of the posterior section of the attention, at present marketed by the Firm. EyePoint Prescribed drugs is headquartered in Watertown, Massachusetts.
STATEMENTS BY EYEPOINT PHARMACEUTICALS SAFE HARBOR UNDER THE PRIVATE SECURITIES LITIGATION ACT OF 1995: To the extent that statements made on this press launch handle data that’s not historic, they’re forward-looking statements below the Non-public Securities Litigation Reform Act of 1995. Such statements embody, however are usually not restricted to, statements relating to the usage of proceeds of the providing and different statements recognized by phrases resembling “will”, “potential” , “might”, “could”, “consider”, “intend”, “proceed”, “plan”, “count on”, “anticipate”, “estimate”, “could”, different phrases of comparable that means or the usage of future dates. Ahead-looking statements, by their nature, handle issues which are, to various levels, unsure. Uncertainties and dangers could trigger precise outcomes of EyePoint are materially totally different from these expressed or below -heard in EyePoint’s forward-looking statements. For EyePoint, this contains inventory value volatility and monetary market uncertainties, the continued influence of the COVID-19 pandemic on EyePoint’s enterprise, the medical neighborhood and the worldwide economic system, and the influence normal industrial and financial situations. Extra detailed details about these and different elements that might have an effect on EyePoint’s precise outcomes are set forth in EyePoint’s filings with the SEC, together with its Annual Report on Kind 10-Ok for the fiscal 12 months ended December 2021, as revised or supplemented by its quarterly stories. on Kind 10-Q and different paperwork filed with the SEC. All forward-looking statements contained on this press launch converse solely as of the date of this press launch. EyePoint undertakes no obligation to replace or revise any forward-looking statements, whether or not on account of new data, future occasions or in any other case.
Inexperienced Room Communications